Modified Surface of PLGA Nanoparticles in Smart Hydrogel

Status Completed

Clinical Trial Summary

Nanoparticles containing antibiotic were prepared and incorporated in in situ gel to treat recurrent endodontic infections

Clinical Trial Description

Enterococcus faecalis is the main cause of endodontic infections and form biofilm on dentin, resulting in treatment-resistant periradicular lesions. To overcome these problems, antibacterial nanoparticles were used because of their small size, sustained release and positive charge which interact with the negatively charged surface of bacterial cell causing its destruction. In this light, Ciprofloxacin hydrochloride (CIP) in chitosan coated PLGA nanoparticles (CIP-CS-PLGA-NPs) and free CIP were embedded in Pluronic® 407/188 to form thermosensitive gels(F1) and (F2) respectively, that were investigated in terms of viscosity, gelation temperature and in-vitro release. The antibacterial efficacy of F1 and F2 were clinically investigated on patients then compared to CIP and Ca(OH)2 pastes by determining bacterial reduction percent and biofilm inhibition assay ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05442736
Study type	Interventional
Source	British University In Egypt
Contact
Status	Completed
Phase	Early Phase 1
Start date	April 2, 2022
Completion date	April 16, 2022

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT03309358` - A Study of the Safety and Tolerability of Inhaled SNSP113 in Healthy Subjects and Subjects With Stable Cystic Fibrosis	Phase 1
Recruiting	`NCT02922998` - CD64 and Antibiotics in Human Sepsis	N/A
Completed	`NCT04212403` - Antibiotic Prophylaxis in Transurethral Prostate Resection (TURP) and Transurethral Bladder Tumour Resection (TURB)	N/A
Recruiting	`NCT05502380` - Broad-spectrum Antibiotic Prophylaxis in Tumor and Infected Orthopedic Surgery	Phase 3
Not yet recruiting	`NCT04462133` - Optimal Tailored Treatment for H. Pylori Infection	N/A
Completed	`NCT03535324` - Opportunities for Antibiotic Optimisation and Outcomes Improvement in Patients With Negative Blood Culture (NO-BACT)	N/A
Recruiting	`NCT05950984` - Medical Device (MD) Derived Pharmacokinetic (PK) Parameters for Vancomycin (MD-PK)
Withdrawn	`NCT04230746` - Effect of Antibiotics on Urinary Microbiome	Early Phase 1
Active, not recruiting	`NCT03865706` - Inulin for Infections in the Intensive Care Unit	Phase 2
Not yet recruiting	`NCT06028217` - Chinese Hospital Acquired Pneumonia Collaboration Network: Epidemiology, Diagnosis and Treatment
Recruiting	`NCT05391035` - The Antibiotic Guardian Study- Clinical Evaluation of a Novel, Rapid Diagnostic for Gonorrhoea and Mycoplasma Infections.
Recruiting	`NCT05224401` - Pivmecillinam With Amoxicillin/Clavulanic Acid for Step Down Oral Therapy in ESBL UTIs	Phase 3
Not yet recruiting	`NCT03855709` - Antibiotic-resistant Bacterial Infection of Hepatic Patients
Terminated	`NCT03535272` - Bismuth Subsalicylate's Role in the Prevention of Travelers' Diarrhea	Phase 3
Recruiting	`NCT05902299` - Evaluation of the Impact of the Modification of Antibiotic Susceptibility Testing on Antibiotic Prescriptions
Recruiting	`NCT05293483` - The Impact of Covid-19 Hospital Care on the Prevalence of MDRO in Indonesia
Recruiting	`NCT05561504` - Helicobacter Pylori Local Prevalence and Antibiotic Resistance
Recruiting	`NCT03606031` - Digestive Microbiota Transplant
Completed	`NCT01573195` - Merck IISP Stewardship Grant for Antibiotic Best Practices	Phase 4
Not yet recruiting	`NCT03857295` - Infections Following NeuroSurgery (INS)